Drug Profile
Ulifloxacin
Alternative Names: AF 3013Latest Information Update: 07 Jul 2009
Price :
$50
*
At a glance
- Originator Nippon Shinyaku
- Developer ACRAF; Optimer Pharmaceuticals
- Class Antibacterials; Fluoroquinolones; Piperazines
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections; Gastroenteritis
Most Recent Events
- 21 Sep 2007 Preclinical trials in Gastroenteritis in USA (unspecified route)
- 21 Sep 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2007) added to the Bacterial Infections antimicrobial activity section
- 27 Nov 2000 Preclinical development for Bacterial infections in Italy (Unknown route)